We evaluated the anti-tumor effect of inhibiting PRMT1 using GSK3368715, the only type I PRMT inhibitor currently in a phase I clinical trial for diffuse large B-cell lymphomas and solid tumors (NCT03666988). This evidence concerns the gene PRMT1 and diffuse large B-cell lymphoma.